CEO Oyler Files to Sell $156M in BeOne Medicines Stock, Upsizing Prior Plan
ONC sits 23% above its 52-week low of $249.12.
Summary
BeOne Medicines CEO John V. Oyler filed to sell $156.1 million in stock, sharply upsizing a prior $45.4 million plan filed days ago, adding to $37 million in recent sales.
Key Events · Ownership and Investor Activity · ONC
-
CEO Proposes $156M Stock Sale
John V. Oyler filed a Form 144 to sell 513,574 ADSs worth approximately $156.1 million, a significant increase from the $45.4 million sale filed on July 10, 2026.
-
Source of Shares: Options and RSUs
The shares to be sold include 425,590 from option exercises over the next three months, 75,723 from previously exercised options, and 12,261 from RSU vesting.
-
Recent Sales Add to Overhang
In the past three months, Oyler and his foundation sold 123,751 shares for $37 million under 10b5-1 plans, indicating ongoing liquidity needs.
-
10b5-1 Plan Adopted March 2026
The sales are executed under a pre-arranged trading plan adopted on March 10, 2026, providing a defense against insider trading allegations but not eliminating negative signaling.
Analysis · ONC · Life Sciences
CEO John V. Oyler filed a new Form 144 to sell 513,574 ADSs worth approximately $156.1 million, a dramatic increase from the $45.4 million sale filed just four days ago. The shares come from option exercises and RSU vesting, and the filing is part of a 10b5-1 plan adopted in March 2026. Combined with recent sales by Oyler and his foundation totaling $37 million over the past three months, the total planned and executed sales represent a significant liquidity event by the CEO. While pre-planned sales under 10b5-1 are routine, the sheer size and rapid escalation raise questions about insider sentiment, especially following strong Q1 results and a major FDA approval.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.7% of the 1694 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONC was trading at $306.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6B. The 52-week trading range was $249.12 to $385.22. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.